文献速递糖尿病

R型维拉帕米联合二甲双胍治疗2型糖尿病患者的随机对照试验

A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项随机、双盲、安慰剂对照试验在单用二甲双胍血糖控制不佳的2型糖尿病患者中评估R型维拉帕米(R-Vera)3个剂量联合二甲双胍的疗效与安全性,共184例受试者随机分组。治疗12周后,R-Vera 300 mg/d组HbA1c降低-0.36(P=0.0373)、450 mg/d组降低-0.45(P=0.0098),均与安慰剂组有显著差异,试验期间未发生低血糖事件。

要点

  • 12周时R-Vera 300 mg/d组HbA1c较安慰剂降低-0.36(P=0.0373),450 mg/d组降低-0.45(P=0.0098)。
  • HbA1c下降与空腹血糖降低及HOMA2-β评分改善相关。
  • 试验期间未发生低血糖事件,R-Vera耐受性良好。

核心结论

  • 在单用二甲双胍血糖控制不佳的2型糖尿病患者中,加用每日两次R-Vera可显著改善血糖控制。
  • R-Vera 300 mg/d具有良好的疗效与安全性特征,作者认为可考虑作为临床实践的合适剂量。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,受试者为单用二甲双胍血糖控制不佳的2型糖尿病患者。
  • 受试者按等比例随机分配至R-Vera 450、300、150 mg/d或匹配安慰剂组,均联合二甲双胍。
  • 共184例合格受试者被随机分配接受R-Vera或安慰剂联合二甲双胍治疗。
  • 主要终点为治疗12周后糖化血红蛋白(HbA1c)的变化。

主要发现

  • 治疗12周时,与安慰剂相比,R-Vera 300 mg/d组HbA1c显著降低-0.36(P=0.0373)。
  • 治疗12周时,与安慰剂相比,R-Vera 450 mg/d组HbA1c显著降低-0.45(P=0.0098)。
  • HbA1c的降低与空腹血糖水平下降及HOMA2-β评分改善相关。
  • R-Vera治疗耐受性良好,试验期间未发生低血糖事件。

关键数值与推荐

  • 主要终点:治疗12周后HbA1c变化。
  • R-Vera 300 mg/d组HbA1c较安慰剂降低-0.36(P=0.0373)。
  • R-Vera 450 mg/d组HbA1c较安慰剂降低-0.45(P=0.0098)。

临床怎么用

  • 作者认为,R-Vera 300 mg/d的疗效与安全性特征可考虑作为临床实践的合适剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There is a medical need for effective insulin-independent antidiabetic drugs that can promote pancreatic β-cell function and have a low risk of hypoglycemia in type 2 diabetes mellitus (T2DM) patients. R-form verapamil (R-Vera), which is able to enhance the survival of β-cells and has higher cardiovascular safety margin compared with racemic verapamil, was developed as a novel approach for T2DM treatment. OBJECTIVE: This randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of 3 dosages of R-Vera added to ongoing metformin therapy in T2DM patients who had inadequate glycemic control on metformin alone. METHODS: Participants were randomly assigned in an equal ratio to receive R-Vera 450, 300, or 150 mg per day, or matching placebo, in combination with metformin. The primary endpoint was change in hemoglobin A1c (HbA1c) after 12 weeks of treatment. RESULTS: A total of 184 eligible participants were randomized to receive either R-Vera or placebo plus metformin. At week 12, significant reductions in HbA1c were observed for R-Vera 300 mg/day (-0.36, P = 0.0373) and 450 mg/day (-0.45, P = 0.0098) compared with placebo. The reduction in HbA1c correlated with decreasing fasting plasma glucose levels and improved HOMA2-β score. Treatment with R-Vera was well tolerated with no hypoglycemic episodes occurring during the trial. CONCLUSION: Addition of R-Vera twice daily to ongoing metformin therapy significantly improved glycemic control in T2DM patients. The favorable efficacy and safety profile of R-Vera 300 mg/day can be considered as the appropriate dose for clinical practice.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang CY, Huang KC, Lu CW, et al. A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2022. PMID: 35917580. doi:10.1210/clinem/dgac436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。